User profiles for Clément Morgat
 | Clément MorgatDepartment of Nuclear Medicine, University Hospital of Bordeaux Verified email at chu-bordeaux.fr Cited by 712 |
Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors
Receptors for some regulatory peptides are highly expressed in tumors. Selective
radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit …
radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit …
Gallium-68: chemistry and radiolabeled peptides exploring different oncogenic pathways
Early and specific tumor detection and also therapy selection and response evaluation are
some challenges of personalized medicine. This calls for high sensitive and specific …
some challenges of personalized medicine. This calls for high sensitive and specific …
Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy
…, MA Quinto, C Morgat… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being
increasingly used at earlier stages, such as for treating minimal residual disease. The aim of …
increasingly used at earlier stages, such as for treating minimal residual disease. The aim of …
Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors
C Morgat, G MacGrogan, V Brouste… - Journal of Nuclear …, 2017 - Soc Nuclear Med
A growing body of evidence suggests that gastrin-releasing peptide receptor (GRPR) might
be a valuable target in breast cancer. To understand which patients can be potential …
be a valuable target in breast cancer. To understand which patients can be potential …
[HTML][HTML] Comparison between three promising ß-emitting radionuclides, 67Cu, 47Sc and 161Tb, with emphasis on doses delivered to minimal residual disease
C Champion, MA Quinto, C Morgat… - Theranostics, 2016 - ncbi.nlm.nih.gov
PURPOSE: Radionuclide therapy is increasingly seen as a promising option to target minimal
residual disease. Copper-67, scandium-47 and terbium-161 have a medium-energy β-…
residual disease. Copper-67, scandium-47 and terbium-161 have a medium-energy β-…
[HTML][HTML] Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
Background Targeted radionuclide therapy (TRT) is gaining importance. For TRT to be also
used as adjuvant therapy or for treating minimal residual disease, there is a need to increase …
used as adjuvant therapy or for treating minimal residual disease, there is a need to increase …
Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1
C Morgat, FL Vélayoudom-Céphise, P Schwartz… - European journal of …, 2016 - Springer
Context Somatostatin receptor scintigraphy with 111 In-pentetreotide (SRS) is used to detect
duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type …
duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type …
[HTML][HTML] Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples
C Morgat, R Schollhammer, G Macgrogan, N Barthe… - PloS one, 2019 - journals.plos.org
The Gastrin-Releasing Peptide Receptor (GRPR) is over-expressed in estrogen receptor (ER)
positive breast tumors and related metastatic lymph nodes offering the opportunity of …
positive breast tumors and related metastatic lymph nodes offering the opportunity of …
[HTML][HTML] Theranostics of primary prostate cancer: Beyond PSMA and GRP-R
Simple Summary The accurate assessment of the aggressiveness and localization of primary
prostate cancer lesions are essential for treatment decision making. Around 15% of lesions …
prostate cancer lesions are essential for treatment decision making. Around 15% of lesions …
[HTML][HTML] Design and preclinical evaluation of a novel apelin-based PET radiotracer targeting APJ receptor for molecular imaging of angiogenesis
…, S Fernandez, P Brige, G Hache, A Tintaru, C Morgat… - Angiogenesis, 2023 - Springer
APJ has been extensively described in the pathophysiology of angiogenesis and cell
proliferation. The prognostic value of APJ overexpression in many diseases is now established. …
proliferation. The prognostic value of APJ overexpression in many diseases is now established. …